Lintuzumab  (Synonyms: 林妥珠单抗; SGN-33; HuM-195)

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Lintuzumab (5 μg/mL, 0.1-2 小时) 诱导 HL60 细胞中 CD33 磷酸化和 Shp-1 磷酸酶的募集^[2]。
Lintuzumab (2500 ng/mL) 显著降低 KG-1 细胞中 IL-8、MCP-1、IP-10 和 RANTES 等致瘤生长因子的产生^[2]。
Lintuzumab (0.1 ng/mL-10 μg/mL) 发挥多种效应功能，包括在 AML 细胞系中介导 ADCC 和 ADCP^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Lintuzumab (3-30 mg/kg，静脉注射，4 次) 与对照组相比，显著提高了 HL-60 异种移植小鼠的生存率^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

945  [NCBI]

P20138

145.24 kDa

166089-32-3

液体

Colorless to light yellow

林妥珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Siglec-3/CD33 Protein, Human can bind Lintuzumab. The EC₅₀ for this effect is 1.206 ng/mL.

• [1]. Lintuzumab

  [2]. Sutherland, M. K., et al., (2009). Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs, 1(5), 481–490.  [Content Brief]